tert-butyl (5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-cyanothiophen-3-yl)carbamate | 1198082-48-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl (5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-cyanothiophen-3-yl)carbamate
• CAS: 1198082-48-2
• 化学式: C₁₈H₃₀N₂O₃SSi
• 分子量: 382.599
• InChiKey: BISVXGLZZNJEHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.53
• 重原子数：
  25.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  71.35
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-cyanothiophen-3-yl)carbamate 在 盐酸羟胺 、 三乙胺 作用下， 以 乙醇 为溶剂， 以30%的产率得到
  参考文献：
  名称：

  2-(3-Thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acids as inhibitors of HCV NS5B RdRp

  摘要：

  A series of 2-(3-thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acid inhibitors of the hepatitis C virus (HCV) NS5B polymerase enzyme are reported. Sulfonyl urea substituted analogs in this series proved to be the most potent active site non-nucleoside inhibitors of NS5B reported to date. These compounds had low nanomolar enzyme inhibition across HCV genotypes 1-3 and showed single digit micromolar inhibition in the HCV replicon assay. This improved cell-based activity allowed the binding mode of these compounds to be probed by selection of resistant mutations against compound 21. The results generated are in broad agreement with the previously proposed binding model for this compound class. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.06.106
• 作为产物：
  描述：

  3-tert-butyloxycarbonylamino-4-thiophene carbonitrile 、 叔丁基-(2-碘乙氧基)二甲基硅烷 在 lithium diisopropyl amide 作用下， 以24%的产率得到tert-butyl (5-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-cyanothiophen-3-yl)carbamate
  参考文献：
  名称：

  2-(3-Thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acids as inhibitors of HCV NS5B RdRp

  摘要：

  A series of 2-(3-thienyl)-5,6-dihydroxypyrimidine-4-carboxylic acid inhibitors of the hepatitis C virus (HCV) NS5B polymerase enzyme are reported. Sulfonyl urea substituted analogs in this series proved to be the most potent active site non-nucleoside inhibitors of NS5B reported to date. These compounds had low nanomolar enzyme inhibition across HCV genotypes 1-3 and showed single digit micromolar inhibition in the HCV replicon assay. This improved cell-based activity allowed the binding mode of these compounds to be probed by selection of resistant mutations against compound 21. The results generated are in broad agreement with the previously proposed binding model for this compound class. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.06.106